Review explores cGAS-STING pathway's role in digestive diseases and its therapeutic potential.
The increasing global burden of digestive diseases, coupled with the complexity of their pathogenesis, underscores the urgent need for in-depth research into precise organ-specific therapies. The cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway, a crucial innate immune signaling axis, has garnered considerable attention for its roles in immune defense, inflammation regulation, tumorigenesis, and tissue homeostasis. In this review, we outline common digestive diseases linked to the cGAS–STING pathway, elucidate its mechanistic contributions to these conditions, and provide a detailed analysis of how targeting this signaling axis may influence disease progression. We hope this review will offer a theoretical foundation for developing novel therapeutics and innovative treatment strategies for digestive diseases, thereby contributing to improved clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: